person · Reporting owner
Maloberti Renaud Bertrand
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionik Laboratories Corp.BNKL · Entity 112055 | Chief Commercial Officer | June 11, 2018 | June 26, 2018 |
| ENDRA Life Sciences Inc.NDRA · Entity 8083 | Chief Commercial Officer | March 28, 2022 | March 30, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionik Laboratories Corp.
Report date June 11, 2018 · Filed June 26, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.05 · Expires 2025-06-11 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-06-11 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The options shall vest 250,000 on June 11, 2019, 250,000 on June 11, 2020 and 250,000 on June 11, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The options shall vest 250,000 on June 11, 2019, 250,000 on June 11, 2020 and 250,000 on June 11, 2021.
ENDRA Life Sciences Inc.
Report date March 28, 2022 · Filed March 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2032-03-28 | Direct | 186,430 |
Reported balance
After 2022-03-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-28 · Grant · Acquired 186,430 · Balance 186,430 F1: This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 28, 2022 Filed Mar 30, 2022 21:16 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 186,430 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001209191-22-021625 · doc4.xml · derivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,430 Underlying: Common Stock · 186,430 shares Expires 2032-03-28 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:11 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001209191-21-025850 · doc4.xml · derivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-04-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 21:18 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | SaleCommon Stock | 13,696 | $1.10 | $15,065.60 |
DisclosureSEC source: 0001209191-21-003597 · doc4.xml · nonDerivative · entry 2 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,580 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 21:18 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | SaleCommon Stock | 6,304 | $1.05 | $6,619.20 |
DisclosureSEC source: 0001209191-21-003597 · doc4.xml · nonDerivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,276 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 08, 2021 Filed Jan 9, 2021 00:11 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | SaleCommon Stock | 8,731 | $0.94 | $8,207.14 |
DisclosureSEC source: 0001209191-21-002828 · doc4.xml · nonDerivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,580 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 trading plan to pay withholding taxes due in connection with the vesting of certain restricted stock units. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 00:15 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | SaleCommon Stock | 11,269 | $0.94 | $10,592.86 |
DisclosureSEC source: 0001209191-21-002371 · doc4.xml · nonDerivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,311 F1 · kind: Represents shares sold pursuant to a 10b5-1 trading plan to pay withholding taxes due in connection with the vesting of certain restricted stock units. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 12:00 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | SaleCommon Stock | 25,000 | $0.73 | $18,250.00 |
DisclosureSEC source: 0001209191-20-064584 · doc4.xml · nonDerivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,580 F1 · kind: Represents shares sold pursuant to a 10b5-1 trading plan to pay withholding taxes due in connection with the vesting of certain restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.73 to $0.75, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. F3 · balance_after: Includes unvested restricted stock units. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:01 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | SaleCommon Stock | 10,000 | $0.81 | $8,100.00 |
DisclosureSEC source: 0001209191-20-058450 · doc4.xml · nonDerivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,580 F1 · kind: Represents shares sold pursuant to a 10b5-1 trading plan to pay withholding taxes due in connection with the vesting of certain restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.83, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. F3 · balance_after: Includes unvested restricted stock units. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 11:22 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | SaleCommon Stock | 10,000 | $0.72 | $7,200.00 |
DisclosureSEC source: 0001209191-20-053429 · doc4.xml · nonDerivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,580 F1 · shares: Represents shares sold pursuant to a 10b5-1 trading plan to pay withholding taxes due in connection with the vesting of certain restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.72 to $0.74, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. F3 · balance_after: Includes unvested restricted stock units. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 20:40 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantCommon Stock | 86,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024214 · doc4.xml · nonDerivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,580 F1 · shares: Represents restricted stock units granted in lieu of a portion of the Reporting Person's cash salary. Subject to continued employment, the restricted stock units vest each day, pro rata based on the number of days between the grant date and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| January 25, 2020 Filed Jan 28, 2020 22:03 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 20,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001209191-20-005187 · doc4.xml · derivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-25 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning January 25, 2021. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:50 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock option (right to buy) · Derivative | 42,859 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-19-060088 · doc4.xml · derivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,859 Underlying: Common Stock · 42,859 shares Expires 2029-12-11 F1 · derivative.exercise_date: These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date. Read SEC document |
| May 28, 2019 Filed May 30, 2019 23:33 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 35,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001209191-19-033525 · doc4.xml · derivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-05-28 F1 · derivative.exercise_date: These Stock Options become exercisable in three equal annual installments beginning on May 28, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.